trending Market Intelligence /marketintelligence/en/news-insights/trending/uvpgtcwuej4k8auypva1fq2 content esgSubNav
In This List

Halozyme appoints former Bristol-Myers exec to board

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation

Blog

Using Credit Analytics to Avoid Mispricing Insurance Premiums

Blog

Post-Webinar Q&A: Integrating Climate Risks into Credit Risk Portfolios


Halozyme appoints former Bristol-Myers exec to board

Halozyme Therapeutics Inc., a San Diego-based biotechnology company, appointed Bernadette Connaughton to its board.

Connaughton most recently worked with Bristol-Myers Squibb Co. as an intercontinental president for a region that included China, Latin America, Central and Eastern Europe and the Middle East. In this role, she developed the commercialization strategy for a number of products, including Opdivo, Yervoy, Sprycel, Daklinza and Orencia.

Halozyme researches, develops and commercializes human enzymes and other drug candidates in the U.S. and Switzerland, and internationally.